On August 27th the results of a trial of an anti-inflammatory medicine called canakinumab were released at a meeting, in Barcelona, of the European Society of Cardiology. Press reports were gushing, telling of a fabulous new drug that would cut the risk of heart attacks and cancer at the same time. The coverage was so positive that people reading or hearing it might have been forgiven for wondering when this treatment would be available to everyone. The answer is probably “never”, for canakinumab’s benefits have been greatly oversold. This trial was, nevertheless, important. Though it offered no immediate treatment, it confirmed what has long been suspected—that inflammation is an important factor in heart disease.
The excitement surrounding this trial is therefore scientific rather than clinical. It provides evidence for a possible new way of treating coronary-artery disease, by developing ways to inhibit inflammation.
The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: A wonder drug for heart disease that isn’t that wonderful